Cyclerion Therapeutics, Inc. (CYCN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-1.4M -700K 0 700K 1.4M 2.1M Q3 '21: 348K Q4 '21: 533K Q1 '22: 711K Q2 '22: 306K Q3 '22: 0 Q4 '22: -720K Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 194K Q4 '24: 1.8M Q1 '25: 81K Q2 '25: 93K Q3 '25: 875K Q4 '25: 1M Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '21: -11.3M Q4 '21: -14.3M Q1 '22: -13M Q2 '22: -13.4M Q3 '22: -4.5M Q4 '22: 12.4M Q1 '23: -3.3M Q2 '23: -1.9M Q3 '23: -6M Q4 '23: -1.8M Q1 '24: -1.6M Q2 '24: -1.4M Q3 '24: -1.1M Q4 '24: 502K Q1 '25: -1.5M Q2 '25: -1.7M Q3 '25: -1M Q4 '25: -838K Q1 '26: -3.2M Q2 '26: -1.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '21: -11.3M Q4 '21: -10.8M Q1 '22: -13M Q2 '22: -13.4M Q3 '22: -10.5M Q4 '22: -7.2M Q1 '23: -7M Q2 '23: -4.2M Q3 '23: 7.6M Q4 '23: -1.7M Q1 '24: -1.5M Q2 '24: -1.3M Q3 '24: -723K Q4 '24: 530K Q1 '25: -1.4M Q2 '25: -324K Q3 '25: -976K Q4 '25: -799K Q1 '26: -3.2M Q2 '26: -1.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '21: -7.9M Q4 '21: -8.6M Q1 '22: -12.8M Q2 '22: -10.8M Q3 '22: -9.9M Q4 '22: -7M Q1 '23: -6.2M Q2 '23: -6.6M Q3 '23: -6.9M Q4 '23: -1.5M Q1 '24: -1.9M Q2 '24: -1.1M Q3 '24: -1.7M Q4 '24: 360K Q1 '25: -968K Q2 '25: -503K Q3 '25: -264K Q4 '25: -1.6M Q1 '26: -1.2M Q2 '26: -1.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '18: -26.6M Q2 '18: -22.9M Q3 '18: -26.5M Q4 '18: -25M Q1 '19: -36.1M Q2 '19: -26.2M Q3 '19: -24.5M Q4 '19: -22.3M Q1 '20: -30.6M Q2 '20: -14.3M Q3 '20: -15.1M Q4 '20: -14.1M Q4 '21: -8.6M Q4 '22: -7M Q1 '25: -968K Q2 '25: -503K Q1 '26: -1.2M Q2 '26: -1.4M Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '21: 35.7M Q3 '21: 43.3M Q1 '22: 43.4K Q2 '22: 2.2M Q3 '22: 2.2M Q1 '23: 2.2M Q2 '23: 2.3M Q3 '23: 2.8M Q1 '24: 2.5M Q2 '24: 2.5M Q3 '24: 2.5M Q1 '25: 2.6M Q2 '25: 3.1M Q3 '25: 3.2M Q1 '26: 4.2M Q2 '26: 4.3M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q3 '20: -2.97 Q4 '20: -2.57 Q1 '21: -2.23 Q2 '21: -1.98 Q3 '21: -1.65 Q4 '21: -1.34 Q1 '23: -17.51 Q2 '23: -13.18 Q3 '23: -5.63 Q4 '23: -2.25 Q1 '24: 0.33 Q2 '24: 1.63 Q3 '24: -1.38 Q4 '24: -1.21 Q1 '25: -1.15 Q2 '25: -0.73 Q3 '25: -0.74 Q4 '25: -1.16 Q1 '26: -1.36 Q2 '26: -1.66 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.